Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is in a strong position for future growth with promising developments in its pipeline, including new diagnostic and therapeutic opportunities. The company's recent financial performance has been impressive, with outperformance in all product segments and a clean earning per share beat. The potential for upcoming catalysts, such as FDA approvals and new partnerships, make this stock an attractive investment opportunity. The company's diversified portfolio and strong partnerships also provide stability and potential for continued growth in the highly competitive healthcare industry.

Bears say

Lantheus Holdings is facing a transitional period with the search for a new CEO, which could lead to potential instability and uncertainty within the company. However, the company's strong product portfolio and solid financials provide some stability and potential growth opportunities in the near future with the launch of PYL TruVu, the re-acceleration of Pylaify and TruVu, and the anticipated re-acceleration of the company's revenue in 2027 after the securement of a new TPT status for TruVu. Overall, the negative outlook on the stock is driven by the potential risks and uncertainties surrounding the CEO search and the transitional period for the company.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.